^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Puyouheng (pucotenlimab)

    i
    Other names: HX008, HX 008, HX-008, LP001, AK103
    Company:
    HanX Biopharma, Lepu Med, Taizhou Hanzhong Biopharma
    Drug class:
    PD1 inhibitor
    Related drugs:
    3d
    TRIUMPH-AM: Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Shanghai Zhongshan Hospital
    New P2 trial
    |
    temozolomide • Lenvima (lenvatinib) • Puyouheng (pucotenlimab)
    5d
    A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Fudan University
    New P2 trial • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    15d
    MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) (clinicaltrials.gov)
    P1/2, N=160, Not yet recruiting, Lepu Biopharma Co., Ltd.
    New P1/2 trial • Checkpoint inhibition
    |
    GPC3 (Glypican 3)
    |
    Avastin (bevacizumab) • Puyouheng (pucotenlimab)
    29d
    Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Sun Yat-sen University
    New P2 trial • pMMR
    |
    capecitabine • oxaliplatin • Puyouheng (pucotenlimab)
    2ms
    Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, Fudan University
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    2ms
    Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sir Run Run Shaw Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    2ms
    Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC (clinicaltrials.gov)
    P2, N=21, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Fumena (vorolanib)
    2ms
    MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, West China Hospital
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    2ms
    Clinical Efficacy of Pucotenlimab Combined with Lenvatinib and SOX Versus SOX Alone in Patients with HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Center Randomized Controlled Trial (ChiCTR2600116583)
    P=N/A, N=100, Not yet recruiting, Department of Gastric Surgery, Fujian Medical University Union Hospital; Fujian Medical University Union Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Lenvima (lenvatinib) • oxaliplatin • Puyouheng (pucotenlimab)
    2ms
    Efficacy and Safety of Becotatug Vedotin (EGFR ADC) plus Pucotenlimab and Cisplatin as Neoadjuvant Therapy for LA-HNSCC (ChiCTR2600115972)
    P=N/A, N=30, Not yet recruiting, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    2ms
    Pucotenlimab Combined with Lenvatinib and eribulin in Patients with Advanced Melanoma Failed in First-Line Therapy, a Single-Arm, Open-Label, Multicenter, Phase II Clinical Study (ChiCTR2500114916)
    P=N/A, N=35, Not yet recruiting, Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital
    New trial
    |
    Lenvima (lenvatinib) • irinotecan • Halaven (eribulin mesylate) • Puyouheng (pucotenlimab)
    2ms
    Pucotenlimab Combined with Lenvatinib and eribulin in Patients with Advanced Sarcoma Failed in First-Line Therapy, a Single-Arm, Open-Label, Multicenter, Phase II Clinical Study (ChiCTR2500115523)
    P2, N=33, Not yet recruiting, Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital
    New P2 trial
    |
    Lenvima (lenvatinib) • irinotecan • Halaven (eribulin mesylate) • Puyouheng (pucotenlimab)